| Identification | Back Directory | [Name]
Benzamide, 4-[3-(cyanomethyl)-3-(3',5'-dimethyl[4,4'-bi-1H-pyrazol]-1-yl)-1-azetidinyl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, phosphate (1:1) | [CAS]
1637677-33-8 | [Synonyms]
Povorcitinib phosphate
JAK,Povorcitinib,Povorcitinib phosphate,CLE,Janus kinase,JAK1 inhibitor,Inhibitor,inhibit,Lichen planus,cutaneous lupus erythematosus
Benzamide, 4-[3-(cyanomethyl)-3-(3',5'-dimethyl[4,4'-bi-1H-pyrazol]-1-yl)-1-azetidinyl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-, phosphate (1:1) | [Molecular Formula]
C23H25F5N7O5P | [MOL File]
1637677-33-8.mol | [Molecular Weight]
605.46 |
| Hazard Information | Back Directory | [Uses]
Povorcitinib (INCB54707) phosphate is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib phosphate can be used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) (information extracted from patent WO2021076124A1)[1]. | [References]
[1] Paul Smith, et al. Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp). Patent WO2021076124A1.
[2] Kirby JS, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2023 Oct 21:S0190-9622(23)03037-2. DOI:10.1016/j.jaad.2023.10.034
[3] Zouboulis C C, et al. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment[J]. Journal of the European Academy of Dermatology and Venereology, 2024. |
|
|